Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Other Non-Current Assets (2016 - 2025)

Fate Therapeutics' Other Non-Current Assets history spans 14 years, with the latest figure at $10.2 million for Q1 2025.

  • For Q1 2025, Other Non-Current Assets fell 32.62% year-over-year to $10.2 million; the TTM value through Mar 2025 reached $10.2 million, down 32.62%, while the annual FY2024 figure was $10.2 million, 113533.33% up from the prior year.
  • Other Non-Current Assets reached $10.2 million in Q1 2025 per FATE's latest filing, roughly flat from $10.2 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $15.2 million in Q2 2021 to a low of $9000.0 in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $8.4 million, with a median of $10.2 million recorded in 2024.
  • The largest YoY upside for Other Non-Current Assets was 169088.89% in 2021 against a maximum downside of 99.94% in 2021.
  • A 5-year view of Other Non-Current Assets shows it stood at $33000.0 in 2021, then skyrocketed by 46042.42% to $15.2 million in 2022, then crashed by 99.94% to $9000.0 in 2023, then surged by 113533.33% to $10.2 million in 2024, then changed by 0.0% to $10.2 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Other Non-Current Assets are $10.2 million (Q1 2025), $10.2 million (Q4 2024), and $9000.0 (Q3 2024).